Abstract:Abstract Abstract 4982 The discovery of the V617F point mutation of JAK2 has revolutionized the understanding of the pathogenesis of BCR-ABL-negative myeloproliferative neoplasms (MPNs). Further discoveries of other JAK2 exon 12-15 and MPL mutations have extended the scope of the research in this field. However, a very small proportion of patients with polycythemia vera (PV) and 50% of patients with essential thrombocythemia (ET), as well as primary myelofibrosis (PMF), are negative for JAK2 or MPL mutations. This indicates that other forms of the mutations may exist and needs further evaluation Recently, we treated a patient with ET who did not carry JAK2 V617F or JAK2 exon 12 mutations. The genomic DNA of mononuclear cells from heparin-treated bone marrow as well as he gastric tissue from paraffin embedding samples obtained from the patient was extracted using a DNA extraction kit, according to the manufacturer's instruction (Promega, Madison, WI, USA), and stored at -20°C. For mutation analysis of the JAK2 exon 12 and exon 14, genomic DNA was amplified respectively by polymerase chain reaction. And the PCR products either 358bp or 308bp were generated by forward primers within the exon 12 or exon 14 and forward primers within the intron 12 or intron 14(primer sequences and PCR conditions are provided on request). The direct sequencing on ABI-3100-Avant was used for mutation detection. No mutation was found within JAK2 exon 12 or exon 14. However, a C/T mutation was detected in intron 14 at the position 14 downstream of the exon 14 in bone marrow cells. Informatively, this mutation was not found in genomic DNA of the gastric tissue. Further more, this novel mutation was not found in all samples from 59 MPN patients in our institute, among which 23 were diagnosed with PV, 22 ET, 12 PMF and 2 MPN-U. No such mutation was demonstrated in bone marrow mononuclear cells from 10 normal subjects. Preliminary results by flow cytometric analysis showed that hematopoietic cells including granulocytes, erythrocytes and megakaryocytes all showed elevated tyrosine kinase activity. We concluded that mutations in JAK2 mRNA splicing region might also contribute to the aberrant signal transduction in hematopoiesis. And direct sequencing for JAK2 whole genomic DNA might be a suitable method for finding novel JAK2 novel mutation in JAK2 negative patients. Further functional study for evaluation of the effect of nucleotide changes within mRNA splicing sequences in wild type and mutated JAK2 cell lines as well as animal models would provide more convincing evidence of the relationship between JAK2 intron mutation and MPNs.. Disclosures No relevant conflicts of interest to declare.

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Analysis of JAK2V617F and MPLW515L/K Mutation in 30 Patients with Early Stage Myeloproliferative Disease

Utility of JAK2 V617F Allelic Burden in Distinguishing Chronic Myelomonocytic Leukemia from Primary Myelofibrosis with Monocytosis.

Janus Kinase 2 Variants Associated with the Transformation of Myeloproliferative Neoplasms into Acute Myeloid Leukemia

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia

Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis—insights from a multicenter study

Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination

Distinct Mutation Landscapes Between Acute Myeloid Leukemia with Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia.

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

Jak2 Mutation in Myeloproliferative Neoplasms: is It Just an Exon Episode?.

JAK Mutations in High-Risk Childhood Acute Lymphoblastic Leukemia.

Clinical Analysis of JAK2 V617F Gene Mutation in 120 Patients with Myeloproliferative Neoplasms

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis

Study on JAK2 V617F Point Mutation in 141 Patients with Chronic Myeloproliferatives Diseases